Key facts
- This page summarizes Rebecca Kuhn's Form 4 filing for NeuroPace Inc (NPCE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Mar 2025, 17:18.
Rebecca Kuhn - 10 Mar 2025 Form 4 Insider Report for NeuroPace Inc (NPCE)
- Reporting relationship
- CHIEF FINANCIAL OFFICER
- Issuer ticker
- NPCE
- Reported as of
- 10 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Mar 2025, 17:18:12 UTC
- Prior SEC filing
- 05 Mar 2025
- Next SEC filing
- 23 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leah Akin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rebecca Kuhn filed Form 4 for NeuroPace Inc (NPCE) on 20 Mar 2025.
Change
- Previous filing in this sequence was filed on 05 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NPCE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +11,700
- Change %
- +9.4%
- Price
- $0.000000
- Shares after
- 136,595
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NPCE
transaction
Derivative
Stock Option (Rt to Buy)
Award
- Transaction value
- $0
- Shares
- +19,850
- Change %
- Price
- $0.000000
- Shares after
- 19,850
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,850
- Exercise price
- $10.04
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on March 3, 2026 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.
Footnote F2
25% of the shares subject to the option vest on March 3, 2026. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.